IP Library › Patent Application 14679944
Patent Application
App. No. 14/679,944

COMPOSITIONS, METHODS AND USES FOR EXPRESSION OF ENTEROBACTERIUM-ASSOCIATED PEPTIDES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/679,944
Abstract

Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.

Claims (21)

1 . A modified vaccinia virus Ankara (MVA) nucleic acid sequence construct comprising:

a nucleic acid sequence of a live, attenuated or modified vaccinia Ankara (MVA) virus encoding:

at least one virulence (V) antigen from a Yersinia spp.;

at least one mammalian secretory signal sequence; and

at least one translational control region.

2 . The nucleic acid construct of claim 1 , wherein the at least one V antigen comprises a full-length V antigen.

3 . The nucleic acid construct of claim 1 , wherein the nucleic acid construct is part of an immunogenic pharmaceutical composition and further includes a pharmaceutically acceptable excipient.

4 . The nucleic acid construct of claim 1 , wherein the at least one mammalian secretory signal sequence is a proleader sequence.

5 . The nucleic acid construct of claim 1 , wherein the proleader sequence comprises at least one of, tissue plasminogen activator (tPA) leader sequence, oc-factor leader sequence, pre-proinsulin leader sequence, invertase leader sequence, immunoglobulin A leader sequence, ovalbumin leader sequence, and P-globin leader sequence or other proleader sequences.

6 . The nucleic acid construct of claim 1 , wherein the at least one translational control region comprises at least one untranslated region (UTR).

7 . The nucleic acid construct of claim 1 , wherein the at least one translational control region comprises at least one internal ribosomal entry site (IRES).

8 . The nucleic acid construct of claim 1 , wherein the Yersinia spp. is Yersinia pestis.

9 . The nucleic acid construct of claim 1 , wherein the translational control region comprises a viral IRES.

10 . The nucleic acid construct of claim 9 , wherein the viral IRES is from encephalomyocarditis virus (EMCV).

11 . The nucleic acid construct of claim 1 , wherein the at least one mammalian secretory signal sequence comprises tissue plasminogen activator (tPA).

12 . The nucleic acid construct of claim 1 , wherein the at least one mammalian secretory sequence comprises tissue plasminogen activator (tPA) and the at least one translational control region comprises a viral IRES.

13 . A method for inducing an immune response to Yersinia spp. in a subject comprising administering a composition of claim 3 to a subject.

14 . The method of claim 13 , wherein the pharmaceutical composition is capable of inducing an immune response in the subject against non-encapsulated and encapsulated Yersinia spp.

15 . A kit comprising;

at least one composition according to claim 3 or at least one construct according to claim 1 ; and at least one container.

16 . The kit of claim 15 , further comprising a delivery device for delivery to a subject.